






Introduction: Malaria is a mosquito borne infection that can lead to anemia in pregnant women, low birth weight, still birth and other adverse birth outcomes. Despite many preventative measures, it is a major cause of maternal and infant mortality in the African region. The World Health Organization (WHO) recommends that women receive three doses of Sulfadoxine/pyrimethamine, as intermittent preventative treatment in pregnancy (IPTp). There is a large gap between the number of women attending antenatal visits and the number receiving IPTp, as well as a large attrition between the first and third dose. 
Methods: A literature review was conducted using the PubMed database between 8/21/2017 and 9/4/17.
Results: Rates of IPTp utilization and adherence lag far behind national targets across the African region. The cited literature elucidated several factors that consistently affected women in accessing the recommended three doses of IPTp. Knowledge of IPTp, the timing of ANC, and inconsistent guidelines for providers were the largest barriers, and these were exacerbated by factors like limited autonomy, mistrust or dislike of medication, stock outs of the drug, and poor patient/ provider interactions. 
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Malaria is a parasitic, mosquito borne illness that disproportionately affects pregnant women and children. In 2015, there were approximately 212 million cases worldwide, with 191 million cases occurring in the African Region, and an estimated 429,000 deaths (World Malaria Report 2016). There are approximately 1.033 billion people living in Sub-Saharan Africa (World Bank, 2016). Mortality is astronomically high and life expectancy is low. The World Health Organization (WHO) classifies the mortality of the region as D and E; the D strata has high child and high adult mortality; the E strata has high child and very high adult mortality (“Atlas of African Health Statistics 2016” WHO, 2016). The life expectancy at birth in the region is only 58 years of age compared to a world average of 71 years of age (World Bank, 2016). Most of these deaths are due to communicable diseases like HIV, lower respiratory infections, diarrheal diseases and Malaria (WHO, 2016).  
1.1	Malaria Clinical Presentation 
The Plasmodium Falciparum parasite is the dominant species on the African continent and is responsible for the majority of malaria deaths globally. P. Falciparum is transmitted through the bite of the female Anopheles mosquito (WHO, March 2017). The parasite infects the salivary glands of the mosquito and is easily transmitted to other hosts when the mosquito feeds. The Anopheles mosquito thrives in warm or tropical climates; it is “anthrophilic,” meaning that it feeds primarily on humans, and is “endophagic,” which means that it can live and feed indoors. This makes it a dangerous vector for disease (CDC, March 2016). In humans, the parasite infects the liver where it is able to multiply. It then travels through the body in the red blood cells. In an established infection, parasites grow within the red blood cells and release daughter parasites called “merozoites,” which can infect other red blood cells and perpetuate the cycle (CDC, March 2016). Clinical disease is marked by the parasite entering the blood stream. 
Malaria may be categorized as “uncomplicated” or “severe.” Symptoms generally appear within 7 days or up to 30 days after infection (CDC, October 2015). Malaria infection occurs in three stages: a cold stage, hot stage and sweating stage.  In the cold stage the patient may experience fever and chills, in the hot stage the symptoms progress to include headache, vomiting and seizures. In the sweating stage, the body temperature returns to normal. Uncomplicated infection is generally self-limiting and may be mistaken for a common cold or flu (CDC, October 2015).  In complicated malaria, the patient experiences hyperparasitemia, having more than 5% of red blood cells infected by the parasite. This can lead to loss of consciousness, seizures, severe anemia, acute respiratory distress and organ failure (CDC, October 2015). 
Malaria is diagnosed using a rapid diagnostic blood test or microscopy. Treatment for uncomplicated malaria consists of artemisinin-based combination therapies (ACT) and oral rehydration (WHO, March 2017). An intramuscular injection of injectable artesunate is used to treat severe malaria along with a three-day course of ACT’s. Injectable artesunate cannot be given to children under the age of 6. ACT’s were adopted as the first line of treatment in 81 endemic countries in 2014 (WHO, March 2017).  
1.2	MALARIA TRANSMISSION AND IMMUNITY
The WHO established zones of high, medium and low transmission. These zones are determined by the size of the mosquito population and the number of infections occurring in children between 2 and 9 years of age. The WHO defines a child as an individual that is under 19 years of age. The WHO defines low transmission areas as areas where malaria transmission is less than 10% for a majority of the year in children ages 2 and 9 (WHO, 2014). Individuals can have their first infection at any age, but generally have their first infection during childhood when immunity is lower. Medium transmission areas are defined as areas with transmission rates between 11-50% in children ages 2 and 9 for most of the year (WHO, 2014). Infections in medium transmission areas tend to be concentrated in child and adolescent populations. The WHO defines an adolescent as an individual between the ages of 10 and 19 years of age. High transmission areas have transmission rates above 50% for most of the year in children ages 2 and 9 (WHO, 2014).  Individuals in high transmission areas may have their first infection at any age, but children are disproportionately affected. 
Individuals living in high transmission areas develop acquired immunity after repeated exposures to the parasite. These individuals are less likely to have severe symptoms after infection. Many adults in high transmission areas have some degree of acquired immunity (CDC, March 2016). Children ages 2 and 9 are most susceptible to malaria because they have not had repeated exposures to the parasite. Infants receive some immunity from their mothers through breastfeeding (CDC, March 2016). This immunity is severely reduced as the child is weened and must rely on their developing immune system rather than immunity provided through breast milk. Although women develop and retain their immunity to the parasite, this immunity is compromised during pregnancy because the parasite is able to replicate in the placental cells (CDC, March 2016).
1.3	MALARIA IN PREGNANCY 
Malaria during pregnancy is a major cause of maternal mortality, anemia, miscarriage, still birth, infant mortality and adverse birth outcomes such as low birth weight or small size for gestational age. In 2015, 20% of stillbirths, 11% of newborn deaths and 10,000 maternal deaths in Sub Saharan Africa were attributed to malaria (“World Malaria Report 2016” WHO, 2016). The effects of the P. Falciparum are most distinct in first time mothers (CDC, March 2016). Women living in high transmission areas may have a higher degree of acquired immunity to the parasite and are often asymptomatic, however, asymptomatic infections can result in adverse birth outcomes and maternal anemia (CDC, March 2016). Women living in low transmission settings have lower levels of acquired immunity and are more susceptible to infection, especially in peak seasons (WHO, May 2017). Pregnant women and children are the most vulnerable segment of the population; the WHO prioritizes prevention efforts to these groups.  
1.4	MALARIA PREVENTION IN PREGNANT WOMEN
The WHO recommends a three-pronged approach to malaria prevention: the use of insecticide treated bed nets (ITN’s), intermittent preventative treatment for pregnant women (IPTp), and effective case management. IPTp is delivered in the form of three Sulfadoxine/Pyrimethamine (IPTp-SP) tablets during routine antenatal care (ANC) visits. IPTp-SP is provided from the end of the first trimester up until the time of delivery, regardless of malaria status (WHO, May 2017).  All women are offered the drug; there is no test and treat method. The logic behind this practice is that women who are positive for malaria will be cured and women who are negative will receive prophylactic benefits. Doses must be given at least one month apart. Women who are positive for Human Immunodeficiency Virus (HIV) are not eligible for IPTp-SP because it can have negative interactions with co-trimoxazole prophylaxis medications (Rassi, C., et.al. November 2016). 
In 2012, the WHO updated recommendations so that women living in high and medium transmission areas receive four ANC visits and three doses of IPTp, and women in low transmission settings receive seasonal doses (WHO, May 2017). Women living in areas with high and stable malaria transmission generally have a higher degree of immunity than women in other areas; however, this immunity is severely depressed during pregnancy. Malaria is often asymptomatic in these women but can still have severe consequences during pregnancy and on the health of the infant (Rassi, C., et.al., November 2016 & WHO, May 2017). 
Thirty-three out of forty-five countries in the African Region have adopted these recommendations. Table 2 details the risk of malaria, adoption of WHO prevention recommendations and use of ANC services by country in the African region. IPTp is widely available in these countries and is offered to all pregnant women free of charge. Women may receive IPTp from public or private hospitals or clinics or from community health workers and midwives (WHO, May 2017). 
1.5	IPTP AVAILABILITY
International funding for malaria prevention has increased incrementally, approximately $0.06 billion per year, from 2005 to 2010; governments of endemic countries contributed 32% of the total $2.9 billion that was spent on vector control, malaria prevention, education and treatment (“World Malaria Report 2016” WHO, 2016). Table 3 details the African region countries that receive WHO funding through the Roll Back Malaria partnership and through the Presidents Malaria Initiative (PMI) through the United States Agency for International Development (USAID). Although funding is lagging behind the targets for the WHO Global Technical Strategy for malaria 2016-2030, commitment to malaria prevention has resulted in a five-fold increase in the delivery of three or more does of IPTp between 2010 and 2016 (World Malaria Report, 2016). The goal of this funding is to improve supply chains of IPTp-SP to public hospitals and to strengthen malaria prevention efforts.
1.6	IPTP UTILIZATION
Despite widespread availability, less than 60% of women are receiving one dose of IPTp and only 31% are getting all three doses, across 20 reporting countries in the African Region (Table 3). These numbers are likely consistent across all countries in the African region (World Malaria Report, 2016). The low rates of IPTp utilization were believed to be the result of stock outs or low rates of ANC attendance; however, recent studies suggest that women are attending multiple ANC visits during their pregnancy and that the supply of IPTp is generally consistent, even in rural areas (WHO, October 2017). The percentage of women attending at least one ANC visit ranges from 61-99% and the percentage of women attending four or more ANC visits ranges from 17-87% (see Table 2). These numbers show that many women are attending at least one ANC visit but are not taking the first dose of IPTp. 
 The large attrition between the first and third dose could mirror trends in ANC attendance. The timing of ANC visits can influence how many doses a woman is eligible to receive. If a woman does not begin attending ANC until late in her pregnancy, she may not have time to receive three doses before she delivers. She may also return too soon, within one month of her previous visit, and not be eligible for subsequent doses at that time. The timing of ANC attendance and the supply chain for IPTp-SP are stumbling blocks for widespread distribution. The low rates of utilization are likely tied to individual level factors that influence a woman’s decision to take the drug. 
1.7	SPECIFIC AIMS
1.	To identify the motivations and deterrents, using the available literature, that influence a woman’s decision to use IPTp-SP to prevent malaria. 




A literature review was conducted using the PubMed database with the guidance of a public health librarian. 
2.1	INCLUSION CRITERIA
To be included in this review, articles and research had to be focused on countries in the African region (as defined by the WHO) and the P. Falciparum malaria species. The search was limited to studies published within the last 5 years. Results included in this study were limited to 2015, 2016 and 2017. The included studies were conducted in countries that have adopted the WHO IPTp recommendations. 
Studies examining the characteristics, attitudes and knowledge of pregnant women toward malaria and IPTp were the targets of this search. 
Search terms included:
Africa AND malaria AND pregnancy AND intermittent preventative treatment
Africa AND malaria AND knowledge AND women 
Africa AND malaria AND prevention AND women











Results were limited to countries in the African region; studies outside of this region were eliminated. Studies had to be focused on the IPTp-SP drug because it is the current WHO recommendation for prevention. Based on title and abstract, studies examining the effectiveness of IPTp-SP or effectiveness of a test and treat approach in preventing adverse birth outcomes were eliminated to focus this review on the current WHO recommendations. Studies with a focus on HIV positive women were eliminated because these women require different types of antimalarial drugs. Studies with a primary focus on bed net use or on young children were eliminated. Literature reviews, cost and policy analyses, and metanalyses were eliminated. 























Table 1. Detailed description of findings from each cited study, including location and setting, sample size and demographics, methods and limitations
					
Author	Location and setting	Sample Size and Demographic Information	Methods	Key Findings	Limitations
Ameh, S., et. al. 2016	Location: NigeriaSetting: Public health facilities in the cross-river state in Nigeria	Sample Size: 400 pregnant women selected from a potential pool of 1539 woman attending ANCDemographic information: 47% of women were in the 15-24 age group and approximately 80% were in their second trimester at the time of ANC registration.	Cross sectional study using a semi- structured questionnaire.	75% of women knew that ITN’s could be used to prevent malaria but only 64% knew that IPTp-SP could prevent malaria. 86% knew the correct dose but only 38% knew the correct timing of the doses. 41% of women reported receiving one dose but only 1% reported receiving two doses.83% of women reported a lack of autonomy that prevented her from seeking ANC without consulting a family member.Only 33% reported receiving the drug with DOT.Women who knew that IPTp-SP could prevent malaria were 22 times more likely to take the drug than those that did not.	Self-report and recall bias.This study did not collect information about use of DOT from health providers.
Doku, D. T., et.al, 2016	Location: GhanaSetting: 6 sub districts in the Tamale Metropolis (in proportion to their population sizes) Health workers randomly selected from 6 facilities	Sample Size: 294 Pregnant women that exceeded 36 weeks or had given birth within 12 weeks. 104 health workers.Demographic Information: Majority of women were 25-29 years old, predominantly Muslim, married. with little formal education. 	Structured questionnaire and observation guide. In-depth interviews and ethnographic techniques.	The provision of clean water was a barrier at all facilities.Many women reported not feeling comfortable asking health workers questions. Malaria and IPTp knowledge among women was found to be low.When asked how to improve ANC use, women said the provision of clean water, increased education of IPTp and improved patient/provider interactions.85% of interviewed staff could correctly explain the purpose of the drug and give the correct schedule for administering the drug.90% of health workers reported using DOT and 56% reported shortages of the drug.	The knowledge of health workers was observed to be high in this area. Results may not generalize to other settings where workers may not be as knowledgeable.
Hurley, E. A., et. al. 2016	Location: MaliSetting: Public health facilities in six rural sites in Mali. The sites were selected because some were available by major roads and others were far from a village center or lacked paved roads	Sample Size: 28 women who were pregnant or had given birth within the past 12 months. 26 focus groups with women who had given birth in the last 2 years, mothers and husbands, and 29 observations across 6 health sites.Demographic information: Not available.	Conducted secondary data analysis on DHS surveys and conducted 28 in depth qualitative interviews and 26 focus groups29 observations across 6 health sites	Secondary analysis found that IPTp-SP coverage estimates in the DHS are likely underestimated 56.2% of women reported one dose and frequently could not describe the purpose of the drug. IPTp-SP utilization is higher than is reported in the DHS. 33.9% of women that took IPTp-SP got it from a non-skilled provider, which is not counted as a dose in the DHS.The main barriers were inconsistent guidelines for IPTp-SP administration, limited autonomy, and poor patient counseling. 	The small number of sites limits the generalizability.
Mbonye, A. K., et.al, 2016	Location: UgandaSetting: Peri-Urban setting.	Sample size: 800 women who delivered within 1 year of the study.Local council members assisted in identifying 32 Health FacilitiesDemographic information: Age range 16-49 with a mean age of 29.8. Majority were married and over half had least primary school education.	Survey 	Most women knew that malaria infection could have adverse effects on a pregnancy and could cause maternal anemia.83% of women attended 1 ANC visit while only 19% attended all 4 visits.A woman’s level of education, employment status, partners level of education, and number of children were factors positively associated with ANC attendance.Most women reported that feeling healthy was a deterrent to seeking ANC. Other sited long wait time, long travel distances to ANC and the lack of support from a partner.	This district is low transmission for most of the year but experiences annual malaria outbreaks, women in this district may be less knowledgeable.Self-report data may be inaccurate
Muhumuza, E., et.al. 2016	Location: Buwunga sub-county in the Bugiri district, UgandaSetting: Community based, 28 villages with one major health center and three smaller health centers	Sample size: 350 randomly selected households with pregnant women or women who had given birth within 12 months of the surveyDemographic information: The mean age of respondents was 26.2 years of age, 80.9% had attained at least primary school education. 58% were Muslim. 52.6% of women had 4 or more pregnancies.	Cross sectional study	Uptake of one dose of IPTp was 63.7% while uptake of two doses was only 42%.  63.1% of women attended their first ANC visit in the second trimester.Only 53.1% of women knew the purpose of IPTp. 47% of women did not know the effects of malaria on pregnant women, 45.1% of women did not know the effects of malaria on the unborn child. Health workers, friends and media were cited as the main source of malaria knowledge Shortages of the drug, long wait times and demand of money by health workers were cited as the main barriers to accessing IPTp.Being knowledgeable about IPTp tablets, ease of access and being served clean water were all positively associated with taking the second dose of IPTp.	The facilities in this study had access to safe clean drinking water, this was not the case in previous studies conducted in this area. These facilities may have higher uptake than others.
Onyeneho, N. G., et. al, 2015	Location: Enugu state, NigeriaSetting: 9 communities across 3 urban areas. 	Sample Size: 246 participants. In depth interviews with12 health workers and 18 women who gave birth within 6 months of the study 24 focus groups with women who did not do interviews their husbands and mothers.Demographic information: Majority of women were married and had received secondary school education. Most of the health workers were women between 28-45. 	Cross sectional design.In depth, semi-structured interviews and focus groups	All participant groups were aware of malaria in their community but many attributed malaria to symptoms of pregnancy or being related to poor hygiene When the focus groups were asked about IPTp, they concluded that it is “too strong” for a pregnant woman and cited a general preference for herbal medicines. Cited barriers to IPTp included poor quality of care and negative interactions with health care workers, stock outs, and difficulties and expenses related to transportation.Health care workers expressed a distrust for the medication and preference to herbs. There was a great deal of mistrust in the government supply and concerns over “fake drugs” or drugs that would cause sickness.	Researchers were unable to make statistical conclusions because of the study design
Owusu-Boateng, I., & Anto, F. 2017	Location: GhanaSetting: government maternity home in Accra, urban area with 7 government health facilities and 1 polyclinic and 5 clinics.This area has a population of 47,900 and participating women came from approximately 36% of the target area	Sample Size:225 Nursing mothers who had given birth within 12 weeks of the study and were seeking postnatal Demographic information: The mean age of the women was 27.1 years, 83% were married, 44.7% had attained primary education and 81.6% were employed. Most women had 2 children.	6- month long, cross sectional hospital based study, in depth interviews and secondary analysis of hospital records	The uptake of IPTp in this study was high, Ghana as an 8-dose policy and ANC attendance was found to be high in this facility. 49.4% of participants began attending ANC in their second trimester.The proportions of IPTp coverage of IPT1 was 98.8%; IPT2, 94.9%; IPT3, 87.5%; IPT4, 55.7% and IPT5, 14.5%.Cost of service, distance to health facilities and waiting time for services were identified as key barriers to IPTp use as well as knowledge of the drug and recommended ANC schedule.	The sample size was adequate for the size of the health facility but could carry more weight if it had been a larger sample. 
Rassi, C., et.al. July 2016	Location: UgandaSetting: 8 Public and Not for profit health facilities. Eastern and West Nile regions of Uganda. The Eastern region has higher than average IPTp uptake, and the West Nile has much lower rates. Researchers selected one urban and one rural district from each region based on convenience	Sample Size: 46 in-depth interviews with 7 district health officials, 15 health workers, 19 women who attended ANC and had given birth within 12 months of the study, and 5 opinion leaders (traditional birth attendants, local councilors, midwives and teachers).Demographic information: Women that lived within walking distance of the clinic and frequently attended ANC.	Cross sectional qualitative study design using semi structured interviews. Thematic analysis of interviews to assess demand side barriers to IPTp.	Interviews showed that distance to the ANC clinic and time spent traveling could be a major deterrent to seeking consistent care and IPTp, especially in later months of the pregnancy. Cost and perceived cost from travel and lost wages were also mentioned as a barrier to seeking care. Some women claimed that they had been charged for IPTp due to stock outs or shortages. The women in this study expressed positive views of health workers and felt that they could trust them if advised to take medication (IPTp). Some women did cite a fear of side effects and a general dislike of medication.That the positive relationship with health workers inspired a positive attitude toward IPTp and taking medication.	Convenience sampling method inconsistencies. Uneven study groups, more women completed IPTp than not.Interactions between health workers and women were not directly observed. 
Rassi, C. et.al, November 2016	Location: UgandaSetting: Same setting used in Rassi C., et.al July 2016.	Sample Size:  this study utilized the same population as Rassi C. et.al, July 2016.	Cross sectional qualitative study design using semi structured interviews. Thematic analysis of interviews to assess supply side barriers to IPTp.	District health officials cited a lack of coordination between districts in relation to the delivery of services, they felt that stronger communication could lead to more effective delivery of IPTp and ANC.Health Workers and district health officials cited inconsistent IPTp guidelines (which impacts the number of doses women receive), but they had a positive attitude toward providing the drug and felt confident in counseling women on the drug. Health workers echoed women concerns about involvement of a male partner and limited autonomy as a barrier to IPTp.Opinion leaders stated that the interactions between women and providers could be improved.Providers and women said that DOT was used consistently, and clean water was available. 	Self-report may not be reliable, and the sample size was small.Researchers examined the reporting practices in the hospital and found them to be inaccurate, the number and timing of ANC appointments as well as IPTp doses may be inaccurate.
Sambili, B., et.al. 2016	Location: TanzaniaSetting:  North western region. It is one of the most densely populated regions in the country.Health facilities were in rural and urban areas across 5 districts. 	Sample Size: 430 women who were pregnant or who had given birth within 12 months of the study selected from 30 sub-villages surrounding 10 randomly selected health facilities Demographic information: Most women were between ages 25-34. 35% had completed primary school. Most women reported giving birth at home. And 73% had between 3-5 children. 	Descriptive cross-sectional study using a structured questionnaire.Questionnaire asked about demographic information, ANC and health education.	Only 29% of women who had delivered prior to the survey had attended the 4 recommended ANC visits and 66% reported that they had received antimalarial drugsOnly 62% of women reported one dose and 11% reported receiving the 3 recommended doses.42% of women did not take IPTP-SP because they did not like medication, 21% said that their partners would not allow it and 20% feared that it would cause miscarriage.	Self-report data may not be accurate. This questionnaire was part of a larger baseline study and did not address each motivating and deterring factor in depth. This study could not assess how perceptions changed over multiple pregnancies. 
Stephen, A. A., et.al, 2016	Location: Gushego, GhanaSetting: Public health clinics	Sample Size: 330 nursing mothers sampled from ANC clinics. 6 ANC staffDemographic Information: A majority of respondents were multigravida and had little formal education.	Questionnaire and observation checklist. 	First time pregnancy was a statistically significant predictor of inadequate IPTp. Being a multigravida was a statistically significant predictor of IPTp use.Age was not a statistically significant predictor of IPTp use.The staff had accurate knowledge of the number of doses and when to administer IPTP, however, all members cited inconsistent supply chain as a reason for inadequate coverage. Unemployment was statistically significant. this is attributed to the inability to afford to travel to the clinic without support from a partner or family member.The timing of ANC visits was the greatest predictor of receiving adequate IPTp- the women who attended more ANC visits also had greater knowledge of malaria in pregnancy and IPTp.	Self- report and recall bias. Results may not be generalizable because it was conducted in the district capital and may not be representative of other sites.
Walker, P. G., et.al. 2017	Location: African RegionSetting: N/A	N/A	Mathematical model to examine the impacts of scaling up IPTp on the rates of low birth weight in Africa due to malaria in pregnancy. Researchers used an existing model of malaria in pregnancy and of low birth weight in newborns, to estimate the risk and benefit of scaling up IPTp-SP coverage.	One model showed that despite the threat of drug resistance, IPTp remains effective in the majority of pregnancies in high transmission areas. Findings from this modeling support the increase of IPTp as a means of preventing malaria in pregnancy and reducing low birth weight.A simulation looking at scaling up IPTp without the threat of resistance and found that it could incrementally reduce rates of low birth weight with each dose the mother received (assuming 2 doses because the base model was created before the 3-dose policy was adopted).The model for low birth weight prevented by IPTp-SP used accurate percentages of treatment failure and SP resistance as well as ITN use; this model found that only 33% of the estimated potential additional low birthweights prevented through scaling up IPTP-SP would have already been covered by an ITN. This means that IPTp-SP could prevent additional low birthweights if ITN use remains consistent. 	Mathematical modeling was based on outdated recommendations for IPTp, due to inaccuracies in reporting, these number are reflective of population trends but may not be fully accurate or account for all factors influencing IPTp use.
Wanzira, H., et.al, 2016	Location: UgandaSetting: 44 urban areas and 166 rural areas.	Sample Size: 1820 women. Demographic information: The majority of women were 25-34 years of age, had attained primary school education and lived in rural areas.	Secondary analysis of the 2014 Malaria indicator survey dataset.Questions about IPTp-SP use were limited to the previous 2 years.	1771/ 1820 women reported attending at least one ANC visit. 822 women reported 2 or more doses of IPTp and 998 women did not take 2 or more doses of IPTp during their last pregnancy. Only 54% of women knew the purpose of IPTp-SP, 78.97% of these were women who had taken 2 or more doses. Odds of taking two or more doses were 10.72 times greater among women with IPTp knowledge than those without. Odds of taking IPTp-SP were 3.19 times higher among women who received care from a skilled attendant than those who received care form an unskilled attendant. Women with 3 or more children were 1.68 times more likely to take IPTp-SP than those with fewer children. Women were older than 35 were 38% less likely to take IPTp-SP than younger women.	This is a secondary analysis of a dataset; demographic characteristics were the focus of this study, but it did not account for other external factors that may influence the low uptake of IPTp-SP
Yaya, S., et.al. 2017	Location: Burkina FasoSetting: N/A	Sample Size: 8111 women between 15-49 years of age.Demographic information: The mean age was 28.63 years, approximately 3/4 of respondents had no formal education. 2/3 of respondents were Muslim. 68.2% lived in urban areas	Secondary analysis of 2014 Burkina Faso Malaria Indicator Survey	Over 80% of women identified ITN’s as a means of malaria prevention but only 6.4% identified preventative medications like IPTp-SP. 1/5 cited good hygiene as a means of prevention.84.7% of women reported taking IPTp-SP during pregnancy68.2% of women in urban areas had accurate knowledge of malaria and 53% of women in rural areas had accurate knowledge of malaria.Women that utilized ANC services were 3.9 times more likely to have accurate malaria knowledge than women who attended less frequently.Analysis showed that the place of residence, religion, level of education and being in possession of a radio or television had significant association with malaria knowledge. Age and wealth had no significant association with malaria knowledge.	This is a secondary analysis of a dataset; demographic characteristics were the focus of this study, but it did not account for other external factors that may influence the low uptake of IPTp-SP.




3.1	NONATTENDENCE OR LATE ANC ATTENDENCE 
The WHO assumes that women will attend a minimum of four ANC visits; however, ANC attendance is far more sporadic than is implied in IPTp guidelines. Women may not attend ANC visits in a time frame that aligns with the recommended schedule for IPTp or receive IPTp from non-skilled providers or community health workers (Hurley, E. A., et. al. 2016). A common response, in many studies, for not seeking ANC care or late attendance was that if the woman did not perceive a problem with her pregnancy or was feeling healthy, she did not see the necessity of an ANC visit (Yoder, P. S., et.al., 2015 & Mbonye, A. K., et.al. 2016). This mindset is especially problematic in high transmission areas where malaria may be asymptomatic. These findings highlight the importance of early and consistent ANC attendance in completing the three recommended doses. The concept of preventative medicine may not carry sufficient weight in the decision to attend ANC or to take IPTp-SP. 
Owusu-Boateng, I., & Anto, F. 2017, took place in Ghana, where eight ANC visits are recommended. Ghana adopted the WHO three dose recommendation, but many mothers receive more than this; the average number of doses in this study cohort was four or five doses. Even with the high uptake, late ANC attendance was identified as the biggest hindrance to women getting three or more doses of IPTp.  While 49.4% of mothers sought ANC in their second trimester, some mothers did not begin seeking ANC until their third trimester. This was also the case in Muhumuza, E., et.al. 2016, 63.1% of mothers did not seek care until their second trimester.  Many Sub-Saharan countries have high uptake of one or more ANC visits with a much lower uptake of IPTp. Late onset of ANC is a common trend and is significant in determining how many doses of IPTp-SP a woman is able to receive (Yoder, P. S., et. al., 2015).  
3.2	SIDE EFFECTS
IPTp- SP is generally well tolerated. Side effects are often minor but may include nausea, vomiting or dizziness. Women have reported nausea as the main side effect to the drug, especially after the first dose or if it is taken without food (Hurley, E. A., et.al., 2016). Some mothers were found to have misconceptions about the drug or fears of it causing severe side effects, birth defects or miscarriage (Hurley, E. A., et.al., 2016 & Sambili, B., et.al, 2016 & Onyeneho, N. G., et.al, 2015). This fear can deter mothers from accepting treatment (Hurley, E. A., et.al., 2016 & Rassi, C., et.al., November 2016 & Yoder, P. S., et.al. 2015 & Mbonye, A. K., et. al. 2016).
Some women were found to be resistant to taking any type of medication while pregnant (Rassi, C., et.al., November 2016 & Hurley, E. A., et.al., 2016). Sambili, B., et.al, 2016 found that women were opposed to IPTp simply because they felt healthy and thought it was unnecessary or because they did not like taking medication. Women in the Yoder, P. S., et.al. 2015 study shared these views of medication during pregnancy, but expressed positive attitudes when it was recommended by a health worker or was described as having positive effects on the pregnancy. Onyeneho, N. G., et. al 2015, found similar attitudes among husbands and mothers of pregnant women, many felt that the drug was unnecessary or too strong for a pregnant woman.
3.3	CHARACTERISTICS OF THE MOTHER AND NUMBER OF PREGNANCIES
Individual characteristics of the mother are less obvious than many other barriers to IPTp.  Some studies have found that the age, income and education level of the mother impacts her willingness to get IPTp, but more research is needed to draw firm conclusions. Even with some uncertainty, awareness of individual characteristics can lead to more effective interventions to improve rates of IPTp utilization. 
3.3.1	AGE
The age of the mother may impact both the frequency and timing of her ANC visits and willingness to take IPTp-SP. Wanzira, H., et.al., 2016 conducted a secondary analysis of demographic factors and found that women older than 35 years are less likely to use IPTp than women between 15-24 years of age, but Stephen, A. A., et. al. 2016, which used a semi structured interview, found that age is not a significant predictor of a woman’s willingness to take IPTp. Both studies note that age may not be the determining factor in a woman’s decision to take IPTp but may correlate with other factors that make it difficult for her to travel to ANC and receive IPTp. Age can impact the level of education that a woman has achieved, her level of autonomy in her household, and the number of pregnancies that she has had. 
3.3.2	EDUCATION 
Muhumuza, E., et.al. 2016 found that education was a significant predictor of both ITN use and IPTp utilization and adherence through a semi structured interview process. Women with higher levels of education were more likely to seek ANC and take IPTp (Owusu-Boateng, I., & Anto, F. 2017 & Sambili, B., et.al, 2016). This suggests that women with higher education are more likely to take preventative measures. 
Yaya, S., et.al. 2017 conducted secondary analysis of the Burkina Faso Malaria Indicator Survey and found that women with secondary education were 29% more likely to take IPTp than women with no formal education; women with higher than secondary education were 93% more likely to take IPTp than women with no formal education. Out of 8,111 women in this study, 5,130 reported taking preventative medicine while pregnant, there was no statistically significant difference between rural and urban uptake. However, this study found significant difference between knowledge of malaria in rural and urban areas. They attributed this difference to women in urban areas having greater access to health communication via TV or radio. 
3.3.3	NUMBER OF PREGNANCIES 
Women in their first pregnancy have been found to be less likely to use ITN’s and IPTp than older women with multiple pregnancies (Walker, P. G., et. al., 2017). Muhumuza, E., et.al. 2016, found that women with two or fewer children were less likely to be knowledgeable about ANC and IPTp. This knowledge can translate into practice: Stephen, A. A., et.al. 2016 found that women with multiple pregnancies were more knowledgeable about IPTp and were more likely to take the first dose and subsequent doses. Number of pregnancies was a positive predictor of IPTp use and early ANC attendance. This is confirmed in Wanzira, H., et.al., 2016, which found that women with more than three children were significantly more likely to use IPTp than women in their first pregnancy. The authors suggest that women with multiple pregnancies are more likely to use IPTp because of multiple exposures to malaria education and messaging.  
There appears to be a limit in the positive association between IPTp use and number of pregnancies. Women with five or more children were found to be less likely to attend ANC (Muhumuza, E., et.al. 2016). Older mothers may be more confident in their pregnancies and less likely to attend ANC if they do not perceive a problem (Stephen, A. A., et.al., 2016 & Wanzira, H., et.al., 2016). 
3.4	TRAVEL AND AUTONOMY 
Women may not attend ANC due to the cost of travel and health care, or the inability to travel to and from the clinic without the assistance of a family member (Hurley, E. A., et.al., 2016 & Rassi, C., et.al., November 2016). Some women have limited control of household finances or voice in their own healthcare (Hurley, E. A., et.al. 2016). This is exacerbated in rural areas where women may also be concerned about indirect costs such as lost wages due to traveling long distances and time spent waiting for an appointment (Rassi, C., et.al., November 2016).  Women who perceived greater cost of travel or IPTp were less willing to take the drug.  Stephen, A. A., et.al., 2016 found that unemployed women were less likely to attend ANC due to the cost of travel and services. If they did attend ANC, they were less likely to take IPTp because of perceived cost.  
Several studies found that long wait times and a lack of approval from household members or a husband were significant in a woman’s decision to take IPTp. In Sambili, B., et.al, 2016, women reported not taking IPTp because their husbands did not approve of the medication. This was also reported in interviews in Mbonye, A. K., et. al. 2016 and in Ameh, S., et.al. 2016, which found that 83% of participants could not receive IPTp without consulting a member of their household. Some women reported that they had long wait times without a partner present and that women attending with their partners were given preferential treatment (Rassi, C., et.al. November 2016).  Many countries encourage men to attend ANC, but deeply engrained cultural practices and concepts of masculinity make this difficult (Sambili, B., et.al, 2016). 
3.5	STOCK OUTS OR LIMITED AVAILABILITY OF IPTP-SP
Many countries in the African Region have made strong commitments to reducing maternal and child mortality. International and national IPTp-SP supply chains were strengthened by the adoption of the WHO three prong approach to prevention (Rassi, C., et.al., July 2016).  Stock outs were believed to be a major bottle neck in IPTp provision (Mbonye, A. K., et.al. 2016 & Ameh, S., et.al. 2016), but research has shown that this is not a primary barrier to IPTp use and adherence (Hurley, E. A., et.al., 2016 & Rassi, C., et.al. July 2016 & Muhumuza, E., et.al. 2016). In Muhumuza, E., et.al. 2016, over 80% of women said that IPTp-SP was easy to access. Many women had IPTp available to them in public hospitals and clinics, yet refused to take the drug (Hurley, E. A., et.al. 2016 & WHO, January 2014 & WHO, May 2017).  
Public hospitals and clinics may experience stock outs; however, stock outs were found to be more likely to occur in private facilities where the national supply chains are weaker (Rassi, C., et.al., July 2016). Private facilities were also more likely to charge women for IPTp; although, some public clinics admitted to charging women for IPTp when they were anticipating a stock out (Rassi, C., et.al., July 2016). This was quantified in Muhumuza, E., et.al. 2016, in which 14.2% of women reported health care workers demanding money for the tablets. 
Muhumuza, E., et.al. 2016, Doku D.T. et. al., 2016, Rassi et. al July 2016 and Stephen, A. A., et.al, 2016 conducted qualitative interviews, women reported that clean water was not always available to them to take IPTp-SP. The scale of this barrier is largely unknown, but it was reported consistently by participants in each of these studies as a hindrance to taking the first dose. Owusu-Boateng, I., & Anto, F. 2017 and Rassi, C et.al, November 2016 explicitly stated that they did not observe stock outs during their study periods. 
3.6	KNOWLEDGE OF IPTP
Wanzira, H., et.al., 2016, Muhumuza, E., et.al. 2016 and Mbonye, A. K., et.al. 2016 examined the impacts of knowledge of IPTp and malaria on a woman’s wiliness to take IPTp-SP. Wanzira, H., et.al., 2016 surveyed nearly 2,000 new and expectant mothers in Uganda and found that only 54% of them knew that IPTp could be used to prevent malaria. The results of Muhumuza, E., et.al. 2016 showed that only 50% of surveyed women knew that IPTp could be used to prevent malaria, 33% of surveyed women admitted that they did not know what IPTp was and 47% of surveyed women did not know the effects of malaria on pregnancy. In both studies, women with greater knowledge of IPTp were more likely to receive multiple doses.  Muhumuza, E., et.al. 2016 calculated that women that were knowledgeable about IPTp were 2.75 times more likely to receive two or more doses than women with less knowledge. Mbonye, A. K., et.al. 2016 found that women with an understanding that IPTp-SP could be used to prevent malaria were 22 times more likely to take the first dose than women who did not understand the purpose of the drug. This knowledge and understanding of the drug has strong implications for willingness to take the first dose and to return for second and third doses. 
The survey used in Muhumuza, E., et.al. 2016 asked women where they learned about malaria and IPTp; 88.2% of women cited health workers, followed by word of mouth (peers) and the media. Wanzira, H., et.al., 2016 found that women receiving care from a skilled attendant were more likely to receive multiple doses of IPTp compared to women receiving care from an unskilled attendant. It was assumed that a skilled attendant has more knowledge of IPTp and when to administer doses. Skilled attendants may also be more practiced in communicating the importance of IPTp to their patients. 
Skilled attendants interviewed in Yoder, P. S., et.al. 2015 and Rassi, C., et.al., November 2016 reported giving extensive counseling on the importance of IPTp and the effects of malaria in pregnancy during routine ANC visits. However, this does not match accounts given by women who chose not to take IPTp. Most women participating in Hurley, E. A., et.al., 2016 could recall being offered the three tablets but could not report their purpose. One woman stated, “I received these treatments, but they did not tell me why”. An observer in this study concurred and said that the providers gave little counseling on the drugs and their purpose. There is an obvious discrepancy in accounts between patients and providers that may be impacting how a woman learns about IPTp and how accurate her knowledge is.  
Onyeneho, N. G., et. al 2015, interviewed the husbands and mothers of pregnant women and found that overall malaria knowledge was very low; many could not accurately describe how malaria is transmitted and blamed sources such as dirty water or too much time spent in the sun. Their findings also reflect a lack of knowledge of the purpose of IPTp and a reluctance to seek treatment if the woman is feeling healthy.
3.7	GUIDELINES FOR PROVIDERS
Nurses and health care providers were found to have extensive and accurate knowledge regarding malaria in pregnancy and IPTp. However, many facilities had inconsistent guidelines for the timing of doses and not all providers were using DOT (Doku, D. T., et.al. 2016 & Mbonye, A. K., et.al. 2016). In Yoder, P. S., et.al. 2015, nurses were able to explain the IPTp recommendations and timing of the doses but could not produce a set of specific written guidelines; this was found to be the case in Rassi, C., et.al., July 2016 as well. These inconsistencies could contribute to the number of women not receiving the three recommended doses. Some providers were using the number of weeks pregnant, generally 12 or more weeks, versus using the quickening, or the detection of fetal movements by the mother, to determine if a woman was eligible for the first dose (Rassi, C., et.al., July 2016 & Yoder, P. S., et.al. 2015). Guidelines for IPTp administration varied widely between countries and facilities. Some providers were also using outdated information that IPTp should not be given in the last month of pregnancy because of a potential link to birth defects (Hurley, E. A., et.al., 2016 & Rassi, C., et.al., July 2016). 
  It is recommended that women take the IPTp-SP tablets during their visit while the provider is present to counsel them on the importance and to ensure the tablets are taken (Doku, D. T., et.al. 2016). In Mbonye, A. K., et.al. 2016, only one third of respondents received IPTp under DOT. Both women and providers stressed the importance of eating before the dose in order to avoid side effects, such as nausea, although this is not a prerequisite to receiving the dose.  Providers reported sending IPTp-SP home with women who had not eaten before the appointment. This is problematic because it invites the possibility that women will not take, or forget to take the dose (Hurley, E. A., et.al., 2016 & Rassi, C., et.al., July 2016 & Yoder, P. S., et.al. 2015). DOT is the gold standard for IPTp provision because it ensures that the dose is taken.
3.8	PATIENT/ PROVIDER INTERACTIONS 
An ideal ANC visit consists of a basic physical examination, blood and urine tests as needed, and counseling about problematic symptoms during pregnancy, malaria prevention and IPTp-SP (Yoder, P. S., et.al. 2015). It is evident that this counseling is necessary but may not always occur. In Yoder, P. S., et.al. 2015 and Rassi, C., et.al., July 2016, providers confessed that they felt overworked. The large number of women coming into clinics each day limited the amount of time spent with each patient and was draining on the staff. Many public hospitals were understaffed; providers, mainly nurses, worked in multiple wards throughout the day. Providers report consistently offering IPTp-SP and counseling each woman on the benefits of IPTp. Muhumuza, E., et.al. 2016 surveyed women about their interaction with their healthcare provider. Most women said that they spent half an hour or more at the appointment, and that the attitude of the provider towards pregnant women was positive.  
Nevertheless, many women reported having poor interactions with rude providers where they were talked down to or scolded for the timing of their ANC visit or resistance to taking IPTp-SP. They reported little or no explanation of IPTp and providers with limited patience for questions and concerns (Rassi, C., et.al., July 2016). Sambili, B., et.al, 2016 was conducted in several rural health facilities where women reported negative provider interactions; they reported being talked down to or even yelled at during ANC visits. Long wait times and poor clinic environment were also commonly cited as reasons for not taking the first dose or returning for subsequent doses (Sambili, B., et.al, 2016 & Muhumuza, E., et.al. 2016). These barriers were also reported in Doku, D. T., et.al. 2016, at a rural clinic in Ghana; overall, women reported acceptable interactions, but 32/184 women reported being yelled at by staff, and nearly one out of ten women reported that they did not feel comfortable asking health workers questions because they did not “behave well toward them,” as one woman stated.
3.9	RECOMMENDATIONS 
The studies included in this review make recommendations for improving access to IPTp-SP and improving adherence to the recommended three doses.  In broad categories these recommendations are to: remove barriers to ANC and encourage early ANC attendance, establish consistent guidelines for providers and training for more effective patient interactions, and to provide women with malaria education that incorporates IPTp (see Table 5).
3.9.1	REMOVING BARRIERS AND ENCOURAGING EARLY ANC ATTENDENCE 
While IPTp-SP is ideally provided for free, there are costs associated with travel and wait times in clinics. Perceived costs and actual costs were found to be equally important to many women. The time spent traveling to the clinic, fear of lost wages, or a lack of support or disapproval from a partner can be deciding factors in the decision to seek ANC and to take IPTp-SP. Despite occasional stock outs, IPTp-SP was found to be widely available; additionally, health care workers seemed to have positive opinions of IPTp and were both knowledgeable about the drug and willing to provide it. Reducing associated costs could improve attitudes toward ANC and likelihood of taking IPTp-SP. 
Convincing women to travel to ANC visits when they do not perceive a problem with their pregnancy can be difficult, but it can be addressed through capacity building in communities. Community health workers can easily provide IPTp-SP in addition to counseling women on its importance. This could reduce some of the burden on public hospitals that are understaffed, reduce wait times and eliminate travel costs (Hurley, E. A.  et.al. 2016, Stephen, A. A., et.al.2016 & Yoder, P. S., et. al 2015). Women may have a greater degree of trust in these workers and may be more receptive to the preventative treatment when it is recommended by people in their communities (Rassi, C., et.al. November 2016 & Sambili, B., et.al. 2016). Community health workers can address questions and concerns and debunk any misconceptions about side effects or adverse effects from IPTp. Engaging husbands or partners to attend ANC visits could also help women with limited autonomy in reaching care and accepting IPTp (Sambili, B., et.al. 2016, Onyeneho, N. G., et. al, 2015). Partners may be more receptive to IPTp-SP use if they are involved in the process, and some of the perceived costs of travel could be reduced.
Encouraging early ANC attendance could drastically improve rates of IPTp utilization. Women who attend early in their pregnancy will be eligible for more doses than women that attend later, and will have more exposure to malaria education and counseling. Walker, P. G., et.al. 2017 created a mathematical model of the impacts of scaling up IPTp-SP distribution, they recommended educational campaigns for malaria that target first time mothers as well as linking them to early ANC. This could make women more confident in their healthcare provider and more likely to take IPTp-SP. (Walker, P. G., et.al. 2017 & Stephen A.A., et.al.2016). 
3.9.2	ESTABLISHING CLEAR GUIDELINES FOR PROVIDERS AND IMPROVING PATIENT INTERACTIONS
It is evident that providers need consistent and accessible guidelines for administering IPTp-SP. The lack of tangible guidelines in facilities leaves room for misinterpretation or use of outdated recommendations (Doku, D.T., et. al. 2015 & Yoder, P. S., et.al. 2015). Providers should be aware that IPTp-SP can be provided even if a woman has not eaten before a visit and can be provided up until the time of delivery. Consistent use of DOT by providers could limit the number of missed doses. Women that take the pills home from their appointments are less likely to take them. DOT also allows time in the appointment for women to ask questions and interact with their provider. Providers should make productive use of this time to counsel women on malaria in pregnancy and stress the necessity of IPTp in high transmission areas because malaria can be asymptomatic.  Even if women are feeling healthy they, and their pregnancy, could benefit from the treatment. 
Training providers to give detailed explanations of IPTp and ensuring women that it is safe could have serious implications or uptake. Women who received a positive explanation of IPTp-SP were more likely to take the drug than women with less knowledge or who had a negative interaction with a provider. The breakdown in communication between healthcare providers and expectant mothers is one of the primary reasons behind the poor uptake of IPTp-SP (Rassi, C., et. al. July 2016). Convincing women to come back for second and third doses is difficult; it requires additional travel costs, time spent waiting at the hospital or clinic and potential lost wages. Some of these barriers can be reduced but it is ultimately the woman’s decision to return to the hospital or clinic. A negative experience with a provider can be a strong deterrent to returning for a drug that does not have obvious effects on most women. 
3.9.3	INCORPORATING IPTP INTO MALARIA EDUCATION
Early malaria education has the potential to assuage fears of side effects and misconceptions about it causing birth defects or miscarriage (Yoder, P. S., et.al. 2015). Correct and consistent information about the benefits of IPTp could mitigate the effects of negative peer experiences with IPTp or ANC. Malaria education tends to focus heavily on ITN use as a means of prevention; many participants in these studies cited the need for more education and information about IPTp (Doku, D.T., et.al. 2016). Incorporating IPTp into malaria education could be highly effective for women living in high transmission areas who are surrounded by malaria messaging from multiple sources.  
Wanzira, H., et.al. 2016 stressed the importance of “behavior change communication” that will emphasize the frequency of IPTp and scheduling of ANC visits. This style of communication could be used to encourage action and adherence. Education alone may encourage women to take the first dose of IPTp, but this does not ensure that they will return for second and third doses. Ameh, S., et. al 2016, Mbonye, A. K., et.al. 2016 and Yaya, S., et.al. 2017, noted that individual level factors like age, level of education and income should be considered when creating educational programs (Owusu-Boateng, I., & Anto, F. 2017). Malaria education should be tailored to each community and delivered in a culturally appropriate way. 
4.0 	DISCUSSION 
4.1	AVAILABILITY AND QUALITY OF DATA 
The literature cited in this review was collected from a total of 7 of the 20 countries (35%) that submitted malaria reports into the WHO World Malaria Report 2016.  Figure 2 is a map of the African Region and distribution of the cited studies. These 7 countries have some of the highest incidence rates for malaria in the African Region (See Table 2). One study was a mathematical model that attempted to utilize the entire African region.  Table 1 provides a detailed description of key findings from each cited study, including location and setting, sample size, demographics, methods and limitations.

Figure 2. Distribution of cited studies through the African region


Overall, this literature review revealed that research into the motivating factors and barriers to IPTp use and adherence is limited. Many studies were conducted before the adoption of the three-dose policy; while they accurately reflect the barriers to receiving the first dose of IPTp, they do not capture the barriers to the later doses. Despite these limitations, the results of these studies are generalizable and can be used to inform further research or educational programs. One strength of the literature cited was the representative populations that were chosen to participate; a wide range of ages, wealth quartiles, education levels, religions, individuals living in rural and urban areas, etc. were captured in these samples. The semi-structured format of many of these studies allowed researchers to gather information of interest as well as allowing women and health care providers to insert their own beliefs, perceptions and challenges. 
4.2	LIMITATIONS OF STUDIES CITED IN THIS REVIEW
Some general limitations of this literature review are the inconsistent years of data collection and uneven distribution of research regarding IPTp utilization across the African region. These studies utilize a population that is already attending ANC and may have different experiences than women than are unable to attend ANC. Additionally, many of these studies utilize self-report data which may not be as accurate as other data collection methods. For those studies using secondary data analysis, the DHS and MICS surveys only capture the number of ANC visits that a woman has attended but cannot capture the timing of her visits, and these data collection tools only count IPTp administered by a skilled provider, IPTp administered by a non-skilled provider is included as a missing data point. More detailed limitations of each individual study can be found in Table 3. 
4.3	OPPORTUNITIES FOR INTERVENTION AND FUTURE DIRECTIONS INFORMED BY THE LITERATURE CITED IN THIS REVIEW
The decision to use IPTp to prevent malaria is a multifaceted issue that is influenced by several interacting and interdependent factors. A wholistic approach to prevention is needed and can be informed by the findings in these studies. Women who choose to take IPTp-SP and adhere to the three-dose schedule generally attend ANC early in their pregnancy and are knowledgeable about the dangers of malaria in pregnancy.  Women who are likely to refuse IPTp, or do not receive all three recommended doses, generally attend ANC later in their pregnancy and have little to no knowledge of malaria or IPTp.  These women may associate a greater cost with ANC, rely on word of mouth and have more misconceptions about the drug and side effects.  These subtle differences present opportunities to intervene and improve the utilization of IPTp.  
As recommended in the literature, countries have the opportunity to increase IPTp utilization by incorporating it into malaria education. Studies have shown a general resistance to medication as well as a reluctance to attend ANC without perceiving a problem with the pregnancy. The concept of preventative medicine must be expanded upon in malaria education. Perceptions of IPTp-SP must be reshaped at the community level; this requires culturally appropriate messaging to shift the view of IPTp from an unnecessary medication to something that is beneficial to the pregnancy. The importance of prevention must also be communicated to women’s husbands and families due to limited autonomy. Encouraging partners to attend ANC could increase uptake and adherence to the four recommended visits and three recommended doses. The support of a partner could also have drastic effects on the number of women receiving the first dose. In order to be effective, this type of messaging must reach several segments of the population and address each of these components.
It is difficult to reduce barriers such as long wait times and cost of services at a national level. The burden on public hospitals can be reduced through capacity building within communities. As noted in several studies, IPTp-SP can be obtained through non-skilled attendants and community health workers. These individuals have the potential to reach the segment of the population that is not attending ANC and to increase IPTp uptake among women who are reluctant to travel due to perceived cost and long wait times. These providers can also work at the community level and may have greater power in shaping the perceptions of ANC and IPTp, they may be able to quell fears of side effects as well as convincing women to seek ANC services even when they are feeling healthy. 
The need for consistent guidelines for providers is evident. Additional training for providers on when to administer IPTp and to explain the benefits could improve IPTp adherence among women already attending ANC.
5.0 	CONCLUSION 
Rates of IPTp utilization and adherence lag far behind national targets across countries in the African region. The literature suggests that despite efforts to increase access to IPTp, there are still major barriers to access and adherence.  Several interdependent factors were prominent in the literature and can be used to inform future research and directions. Individual characteristics like limited knowledge of malaria, fear of side effects, dislike of medication and limited autonomy can be exacerbated by factors like perceived cost, inconsistent administration of the drug by providers, and stock outs of the drug. Although the body of literature and geographical spread of the studies cited in this review are small, these findings were reached with validated measures and representative samples and may be generalized to other parts of the African region.




Table 2. Adoption of IPTp recommendations, ANC attendance and malaria risk across the African region
Country 	Incidence of Malaria/ 1,000 at Risk (2015)	% women attending at least 1 ANC visit (year of collection)	% women attending 4 or more ANC visits (year of collection)	Adopted IPTp Recommendations 
Algeria 	0.002	93 (2013)	67 (2013)	N/A
Angola 	120.4	80 (2007)	No data	Yes	
Benin 	293.7	83 (2014)	58 (2014)	Yes
Botswana 	0.9	94 (2012)	73 (2007)	N/A
Burkina Faso	389.2	94 (2010)	34 (2010)	Yes 
Burundi	126.3	99 (2010)	33 (2010)	No
Cameroon	264.2	83 (2014)	59 (2014)	Yes
Cape Verde	0.2	98 (2005)	72 (2005)	No
Central African Republic 	289.5	68 (2010)	38 (2010)	Yes 
Chad	163.2	55 (2015)	31 (2015)	Yes
Comoros 	5	92 (2012)	49 (2012)	Yes
Congo- Democratic Republic of	246	88 (2014)	45 (2010)	Yes
Congo- Republic of 	173.3	93 (2015)	79 (2015)	Yes
Cote d’Ivorie 	348.8	91 (2012)	44 (2012)	Yes
Equatorial Guinea	215.1	91 (2011)	67 (2011)	N/A
Eritrea	14.5	89 (2010)	57 (2010)	No
Ethiopia 	58.6	41 (2014)	32 (2016)	No
Gabon	232.4	95 (2012)	78 (2012)	Yes
The Gambia 	208.8	86 (2013)	78 (2013)	Yes
Ghana	266.4	91 (2014)	87 (2014)	Yes
Guinea	367.8	85 (2012)	57 (2012)	Yes 













Sao Tome & Principe 	17.8	98 (2014)	84 (2014)	Yes
Senegal	97.6	95 (2015)	47 (2015)	Yes
Sierra Leone	302.8	97 (2013)	76 (2013)	Yes
South Africa 	3.1	97 (2008)	56 (2003)	No
South Sudan 	156	62 (2013)	17 (2010)	Yes
Swaziland	1.4	99 (2014)	76 (2014)	No




Zimbabwe 	114.2	93 (2015)	76 (2015)	Yes
(World Bank, 2016, Who “World Malaria Report 2016” & Who “Eliminating Malaria [Press Release]” 2016).

Table 3. Malaria Funding and reporting countries









Central African Republic 	No	No	No
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Zimbabwe	Yes 	Yes 	Yes 











Table 4. Articles and main themes
	Theme							
Author 	Nonattendance or Late ANC attendance 	Side Effects 	Characteristics of the mother 	Travel and autonomy 	Stock outs, limited availability and perceived cost  	Knowledge of IPTp	Guidelines for providers 	Patient Provider interactions 
Ameh, S., et. al. 2016				*	*			
Doku, D. T., et.al, 2016							*	*
Hurley, E. A., et. al. 2016	*	*		*	*	*	*	
Mbonye, A. K., et.al, 2016	*	*		*	*	*	*	
Muhumuza, E., et.al. 2016			*		*	*		*
Onyeneho, N. G., et.al, 2015		*				*		
Owusu-Boateng, I., & Anto, F. 2017	*			*		*		*
Rassi, C., et.al. July 2016	*	*		*	*			*
Rassi, C et.al, November 2016					*		*	
Sambili, B., et.al. 2016		*		*		*		*
Stephen, A. A., et.al, 2016			*	*				
Walker, P. G., et.al. 2017			*					
Wanzira, H., et.al, 2016			*			*		*
Yaya, S., et.al. 2017			*					





Table 5. Author recommendations for improving IPTp utilization
	Recommendation				
Author 	Removing Barriers and perceived cost 	Encouraging early ANC attendance 	Establishing clear guidelines for providers 	Improving patient/ provider interactions 	Incorporating IPTp into malaria education programs 
Ameh, S., et. al. 2016					*
Doku, D. T., et.al, 2016			*		*
Hurley, E. A., et. al. 2016	*				
Mbonye, A. K., et.al, 2016				*	*
Muhumuza, E., et.al. 2016	*			*	*
Onyeneho, N. G., et.al, 2015				*	*
Owusu-Boateng, I., & Anto, F. 2017		*			
Rassi, C., et.al. July 2016	*	*		*	
Rassi, C., et. al., November 2016	*		*	*	
Sambili, B., et.al. 2016	*	*			*
Stephen, A. A., et.al, 2016	*				
Walker, P. G., et.al. 2017		*			*
Wanzira, H., et.al, 2016		*		*	*
Yaya, S., et.al. 2017				*	*
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